SVB Securities Remains a Hold on Aligos Therapeutics (ALGS)

SVB Securities analyst Roanna Ruiz maintained a Hold rating on Aligos Therapeutics (ALGSResearch Report) today and set a price target of $2.00. The company’s shares closed yesterday at $1.07.

Ruiz covers the Healthcare sector, focusing on stocks such as scPharmaceuticals, Amarin, and Myovant Sciences. According to TipRanks, Ruiz has an average return of -46.7% and an 11.11% success rate on recommended stocks.

The word on The Street in general, suggests a Hold analyst consensus rating for Aligos Therapeutics with a $1.60 average price target.

See the top stocks recommended by analysts >>

The company has a one-year high of $17.97 and a one-year low of $0.98. Currently, Aligos Therapeutics has an average volume of 75.13K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH).

Read More on ALGS:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More